{"id":37133,"date":"2018-02-21T15:13:53","date_gmt":"2018-02-21T13:13:53","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=37133"},"modified":"2018-02-21T15:13:53","modified_gmt":"2018-02-21T13:13:53","slug":"diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","title":{"rendered":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia"},"content":{"rendered":"<p>El passat 14 de febrer es va celebrar al COFB una jornada de <strong>revisi\u00f3 sobre el risc cardiovascular<\/strong> <strong>en pacients amb diabetis <\/strong>(tant tipus I com tipus II). Al llarg de la formaci\u00f3, tamb\u00e9 es van abordar les <strong>novetats<\/strong> que hi ha al voltant d&#8217;aquesta q\u00fcesti\u00f3.<\/p>\n<p>La formaci\u00f3, dirigida a <strong>farmac\u00e8utics de centres d&#8217;atenci\u00f3 prim\u00e0ria<\/strong> i de<strong> l&#8217;administraci\u00f3 sanit\u00e0ria, <\/strong>va estar coordinada per <strong>Roser Vall\u00e8s, vocal d&#8217;Atenci\u00f3 Prim\u00e0ria del COFB<\/strong>.<\/p>\n<h4><span style=\"color: #008080;\"><strong>Programa de la jornada<br \/>\n<\/strong><\/span><\/h4>\n<p>Al llarg del curs es van abordar els seg\u00fcents temes:<\/p>\n<ul>\n<li>Nous <strong>reptes en la salut cardiovascular<\/strong> dels pacients amb diabetis<\/li>\n<li><strong>Objectius terap\u00e8utics<\/strong> en el pacient diab\u00e8tic<\/li>\n<li><strong>Estudis de seguretat cardiovascular<\/strong> dels antidiab\u00e8tics nous: qu\u00e8 i per qu\u00e8?<\/li>\n<li><strong>Revisi\u00f3 cr\u00edtica dels estudis <\/strong><\/li>\n<li>Nous <strong>mecanismes d&#8217;acci\u00f3 i perspectives de futur<\/strong><\/li>\n<li>Estrat\u00e8gies de <strong>tractament terap\u00e8utic multifactorial<\/strong> en un pacient diab\u00e8tic. Casos cl\u00ednics<\/li>\n<\/ul>\n<div class=\"box shadow\"><\/p>\n<h4><strong><span style=\"color: #008080;\">Quadre docent<br \/>\n<\/span><\/strong><\/h4>\n<ul>\n<li><strong>Miguel Camafort<\/strong>, metge especialista s\u00e8nior en medicina interna del Servei de Medicina Interna General, Unitat d&#8217;Hipertensi\u00f3 i Risc Cardiovascular de l&#8217;Hospital Cl\u00ednic de Barcelona.<\/li>\n<li><strong>Xavier Cos<\/strong>, metge d&#8217;atenci\u00f3 prim\u00e0ria, Director del CAP Sant Mart\u00ed de Proven\u00e7als, membre del grup GEDAPS de la CAMFIC, i de la RedGDPS, membre de la <em>Primary Care Diabetes Research Network <\/em>i de la divisi\u00f3 d&#8217;Endocrinologia de la <em>Red de investigaci\u00f3n en actividades prevenitvas y promoci\u00f3n de la salut<\/em> (redIAPP), president de la Primary Care Diabetes Europe (PCDE) des de 2017.<\/li>\n<li><strong>D\u00eddac Mauricio,<\/strong> cap del Servei d&#8217;Endocrinologia i Nutrici\u00f3 de l&#8217;Hospital Germans Trias i Pujol de Badalona, coordinador del <em>Diabetes Research Group<\/em> de l&#8217;Hospital Germans Trias i Pujol, membre de la xarxa CIBERDEM de l&#8217;<em>Instituto de Salud Carlos III. <\/em><\/li>\n<li><strong>Andrea Molina<\/strong>, farmac\u00e8utica, Ger\u00e8ncia d&#8217;Harmonitzaci\u00f3 Farmacoterap\u00e8utica, \u00c0rea del Medicament, Servei Catal\u00e0 de la Salut (CatSalut).<\/li>\n<\/ul>\n<p>[caption id=\"attachment_37142\" align=\"aligncenter\" width=\"620\"]<a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-08.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-37142 size-large\" title=\"D'esquerra a dreta: Miguel Camafort, metge especialista en medicina interna; Andrea Molina, farmac\u00e8utica de l'\u00c0rea del Medicament del CatSalut; Xavier Cos, metge d'atenci\u00f3 prim\u00e0ria i director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, cap del Servei d'Endocrinologia de l'Hospital Germans Trias i Pujol de Badalona i Roser Vall\u00e8s, vocal d'Atenci\u00f3 Prim\u00e0ria del COFB.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-08-1024x683.jpg\" alt=\"D'esquerra a dreta: Miguel Camafort, metge especialista en medicina interna; Andrea Molina, farmac\u00e8utica de l'\u00c0rea del Medicament del CatSalut; Xavier Cos, metge d'atenci\u00f3 prim\u00e0ria i director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, cap del Servei d'Endocrinologia de l'Hospital Germans Trias i Pujol de Badalona i Roser Vall\u00e8s, vocal d'Atenci\u00f3 Prim\u00e0ria del COFB.\" width=\"620\" height=\"414\" \/><\/a> D&#8217;esquerra a dreta: Miguel Camafort, metge especialista en medicina interna; Andrea Molina, farmac\u00e8utica de l&#8217;\u00c0rea del Medicament del CatSalut; Xavier Cos, metge d&#8217;atenci\u00f3 prim\u00e0ria i director del CAP Sant Mart\u00ed de Proven\u00e7als; D\u00eddac Mauricio, cap del Servei d&#8217;Endocrinologia de l&#8217;Hospital Germans Trias i Pujol de Badalona i Roser Vall\u00e8s, vocal d&#8217;Atenci\u00f3 Prim\u00e0ria del COFB.[\/caption]<\/p>\n<p><\/div>\n<h4><span style=\"color: #008080;\"><strong>L&#8217;impacte cardiovascular de la diabetis<br \/>\n<\/strong><\/span><\/h4>\n<p>Per comen\u00e7ar, D\u00eddac Mauricio, cap del servei d&#8217;Endocrinologia de l&#8217;Hospital de la Santa Creu i Sant Pau, va explicar els<strong> conceptes clau per entendre perqu\u00e8 \u00e9s fonamental tenir en compte el risc cardiovascular en pacients amb DM\u00a0(<em>Diabetis Mellitus<\/em>). <\/strong>Cal tenir present que les art\u00e8ries tenen mem\u00f2ria i que\u00a0 l&#8217;impacte cardiovascular d&#8217;una DM de llarg termini mal controlada no \u00e9s el mateix que el d&#8217;una DM acabada de debutar. A m\u00e9s, l&#8217;impacte \u00e9s superior en dones diab\u00e8tiques que en homes.<\/p>\n<p>A continuaci\u00f3, el Dr. <strong>Miquel Camafort<\/strong>, metge internista de l\u2019Hospital Cl\u00ednic i <strong>Andrea Molina<\/strong>, farmac\u00e8utica del CatSalut, van oferir una <strong>explicaci\u00f3 de les causes del \u201cboom\u201d d\u2019estudis i assaigs sobre el risc cardiovascular dels \u00faltims anys en els f\u00e0rmacs m\u00e9s nous per la diabetis<\/strong>. Es tracta d\u2019una exig\u00e8ncia de les ag\u00e8ncies reguladores, entre elles l\u2019EMA, per autoritzar la seva comercialitzaci\u00f3. Consisteix a <strong>estudiar el risc cardiovascular dels nous f\u00e0rmacs<\/strong>, ja que si augmenten el risc, no val la pena iniciar o continuar el tractament. Un altre aspecte que va exposar Camafort van ser els nous estudis que estan en marxa i els que es publicaran en un futur. En els anys vinents, no entraran nous f\u00e0rmacs amb mecanismes d\u2019acci\u00f3 diferents dels que hi ha actualment, per\u00f2 s\u00ed que apareixeran altres principis actius nous dels mateixos grups farmacol\u00f2gics.<\/p>\n<figure id=\"attachment_37152\" aria-describedby=\"caption-attachment-37152\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-05.jpg\"><img decoding=\"async\" class=\"wp-image-37152 size-large\" title=\"Didac Mauricio, durant un moment de la jornada. \" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/cofb.180214-05-1024x683.jpg\" alt=\"Didac Mauricio, durant un moment de la jornada. \" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-37152\" class=\"wp-caption-text\">D\u00eddac Mauricio, durant un moment de la jornada.<\/figcaption><\/figure>\n<h4><span style=\"color: #008080;\"><strong>Casos cl\u00ednics per facilitar la comprensi\u00f3 del tema<\/strong><\/span><\/h4>\n<p>Per cloure la jornada, el Dr. Xavier Cots, metge de fam\u00edlia i expert en DM, conjuntament amb el Dr. Camafort, van exposar dos casos cl\u00ednics de manera interactiva, sobre com tractar pacients diab\u00e8tics que tenen risc cardiovascular elevat.<\/p>\n<p>La vocal d&#8217;Atenci\u00f3 Prim\u00e0ria del COFB, Roser Vall\u00e8s, va destacar que <strong>la formaci\u00f3 &#8220;\u00e9s un tema molt actual i molt important pel correcte tractament dels pacients diab\u00e8tics&#8221;<\/strong>. Aix\u00ed mateix, va exposar que el tema va estar explicat &#8220;de forma molt entenedora&#8221;.<\/p>\n<p style=\"text-align: right;\"><strong>Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n<p><a href=\"https:\/\/www.novonordisk.es\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"wp-image-37135 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/02\/novo-nordisk_416x416.jpg\" alt=\"\" width=\"107\" height=\"107\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Altres publicacions d&#8217;inter\u00e8s:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/blog.cofb.cat\/14-de-novembre-dia-mundial-de-la-diabetis-2\/\" target=\"_blank\" rel=\"noopener\">14 de novembre, Dia Mundial de la Diabetis (Novembre 2016)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/diabetis-puc-fer-alguna-cosa-per-prevenir-la\/\" target=\"_blank\" rel=\"noopener\">Diabetis: puc fer alguna cosa per prevenir-la? (Novembre 2017)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/mes-de-700-farmaceutics-de-barcelona-ajudaran-detectar-el-risc-de-patir-diabetis-la-campanya-atenciodiabetis\/\" target=\"_blank\" rel=\"noopener\">M\u00e9s de 700 farmac\u00e8utics de Barcelona ajuden a detectar el risc de patir diabetis a la campanya #Atenci\u00f3Diabetis (Novembre 2017)<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II). Al llarg de la formaci\u00f3, tamb\u00e9 es van abordar les novetats que hi ha al voltant d&#8217;aquesta q\u00fcesti\u00f3. La formaci\u00f3, dirigida a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":37172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2908,197,2465,200,2198,2466,2385,2882],"class_list":["post-37133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-diabetics","tag-diabetis","tag-diabetologia","tag-glucemia","tag-malalties-cardiovasculars","tag-pacient-diabetic","tag-prevencio-risc-cardiovascular","tag-vocalia-atencio-primaria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-21T13:13:53+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia\",\"datePublished\":\"2018-02-21T13:13:53+00:00\",\"dateModified\":\"2018-02-21T13:13:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"},\"wordCount\":811,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"diab\u00e8tics\",\"diabetis\",\"diabetologia\",\"gluc\u00e8mia\",\"malalties cardiovasculars\",\"pacient diab\u00e8tic\",\"prevenci\u00f3 risc cardiovascular\",\"vocalia atenci\u00f3 prim\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\",\"name\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2018-02-21T13:13:53+00:00\",\"dateModified\":\"2018-02-21T13:13:53+00:00\",\"description\":\"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","og_locale":"ca_ES","og_type":"article","og_title":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","og_url":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2018-02-21T13:13:53+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia","datePublished":"2018-02-21T13:13:53+00:00","dateModified":"2018-02-21T13:13:53+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"},"wordCount":811,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"thumbnailUrl":"","keywords":["diab\u00e8tics","diabetis","diabetologia","gluc\u00e8mia","malalties cardiovasculars","pacient diab\u00e8tic","prevenci\u00f3 risc cardiovascular","vocalia atenci\u00f3 prim\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","url":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/","name":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage"},"thumbnailUrl":"","datePublished":"2018-02-21T13:13:53+00:00","dateModified":"2018-02-21T13:13:53+00:00","description":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II).","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2018\/02\/21\/diabetis-malaltia-cardiovascular-mes-enlla-control-glucemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Diabetis i malaltia cardiovascular: m\u00e9s enll\u00e0 del control de la gluc\u00e8mia"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 14 de febrer es va celebrar al COFB una jornada de revisi\u00f3 sobre el risc cardiovascular en pacients amb diabetis (tant tipus I com tipus II). Al llarg de la formaci\u00f3, tamb\u00e9 es van abordar les novetats que hi ha al voltant d&#8217;aquesta q\u00fcesti\u00f3. La formaci\u00f3, dirigida a [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/37133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=37133"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/37133\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=37133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=37133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=37133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}